A Study Evaluating BPX-501 T Cells and AP1903 for Prevention of Graft Versus Host Disease (GVHD) After Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases

Trial Profile

A Study Evaluating BPX-501 T Cells and AP1903 for Prevention of Graft Versus Host Disease (GVHD) After Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Rivogenlecleucel (Primary) ; Rimiducid
  • Indications Graft-versus-host disease
  • Focus Adverse reactions
  • Acronyms DOTTI
  • Sponsors Bellicum Pharmaceuticals
  • Most Recent Events

    • 14 May 2015 Data published in a Bellicum Pharmaceuticals media release.
    • 14 May 2015 According to a Bellicum Pharmaceuticals media release, data from this study were published in Blood.
    • 14 May 2015 According to a Bellicum Pharmaceuticals media release, data from this study were presented at the American Society of Gene and Cell Therapy (ASGCT) 18th Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top